Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.75 |
| ▸ | TUBB | P07437 | 4/20 | 0.75 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.75 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.75 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.75 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.75 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.75 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.75 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.75 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.75 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.75 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.75 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.75 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.75 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | P4HB | P07237 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25854280 | 1.00 | TUBB4A (0.75) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14130773 | 1.00 | TUBB4A (0.75) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13484555 | 1.00 | TUBB4A (0.75) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14264379 | 1.00 | TUBB4A (0.75) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13613391 | 1.00 | TUBB4A (0.75) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL25853879 | 0.95 | TUBB4A (0.78) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL25641711 | 0.95 | TUBB4A (0.78) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL16996785 | 0.95 | TUBB4A (0.78) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL25854199 | 0.95 | TUBB4A (0.78) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL24226078 | 0.95 | TUBB4A (0.79) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11696956-B2 | Bicyclic peptide ligands specific for EphA2 | BICYCLETX LIMITED (GB) | 2023-07-11 | — | — | US | disclosed |
| US-20220133733-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD38 | BICYCLERD LTD (GB) | 2022-05-05 | — | — | US | disclosed |
| US-8722857-B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8652479-B2 | Antibody-drug conjugates and methods | GENENTECH, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8466260-B2 | Anti-FcRH5 antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8142784-B2 | Antibody-drug conjugates and methods | GENENTECH, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8088378-B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | GENETECH INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100260748-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100215669-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20090202536-A1 | ANTIBODY-DRUG CONJUGATES AND METHODS | GENENTECH, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | GENENTECH, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080171040-A1 | Maytansinoids linked to antibody which binds to ErbB receptor, or which binds tumor-associated antigens or cell-surface receptors | GENENTECH, INC. (US) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202536-A1 | ANTIBODY-DRUG CONJUGATES AND METHODS | ERBB2, EGFR, ERBB4 | TUBB4A 1049/4885TUBB 1421/4885TUBA3C 1997/4885 |
| US-20220133733-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD38 | CD38, CD22, TIMCC | TUBB4A 4364/4885TUBB 4236/4885TUBA3C 3344/4885 |
| US-11696956-B2 | Bicyclic peptide ligands specific for EphA2 | EPHA2, EPHB2, ERBB2 | TUBB4A 2251/4885TUBB 2165/4885TUBA3C 1515/4885 |
| US-20100260748-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | FCGR3B, FCGRT, FCGR1A | TUBB4A 2535/4885TUBB 2712/4885TUBA3C 1054/4885 |
| US-20100215669-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | CD99, CD79B, CD47 | TUBB4A 231/4885TUBB 122/4885TUBA3C 345/4885 |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | CD99, CD79B, CD47 | TUBB4A 231/4885TUBB 122/4885TUBA3C 345/4885 |
| US-20080171040-A1 | Maytansinoids linked to antibody which binds to ErbB receptor, or which binds tumor-associated antigens or cell-surface receptors | ERBB2, EGFR, ERBB4 | TUBB4A 1372/4885TUBB 1593/4885TUBA3C 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.